Navigation Links
India's Asthma Drug Market Will Exceed $400 Million in 2014
Date:12/7/2010

BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that India's asthma drug market will grow from $246 million in 2009 to $403 million in 2014, representing an annual growth rate of ten percent. According to the Emerging Markets report entitled Asthma in India, this growth will be fueled by improved access to medical care, a growing drug-treated population and a rising number of higher-income, brand-conscious asthma patients demanding more-efficacious agents.  

"At $246 million, India's asthma market is close to some European Union countries in dollar terms," said Decision Resources Analyst Manashi Sherawat, M.Sc., Ph.D. "In 2009, multinational pharmaceutical companies accounted for five percent of total sales in the Indian asthma market and while uptake of Western-branded asthma drugs will increase by 2014, these drugs will face fierce competition from less-expensive Indian brands and generics."

According to the report, fixed-dosed combination drugs represent a major opportunity for multinational pharmaceutical companies. The use of combination therapy as maintenance treatment will increase as medical practice in India shifts from treating asthma on an as-needed basis toward treating it as a chronic disease that requires maintenance treatment. Specifically, Indian specialists anticipate that fixed-dosed combination therapies such as long-acting beta(2) agonist (LABA)/inhaled corticosteroid (ICS) will experience the highest uptake.

"Indian specialists struggle with patient compliance when treating asthma. The importance of consistent maintenance therapy is paramount because improved disease outcomes are not achieved unless maintenance therapies are administered consistently. The Indian asthma market would benefit from new, more-convenient therapies, which would boost patient compliance," added Dr. Sherawat.

The new report features extensive primary research of Indian specialists as well as epidemiology data.

About Emerging Markets ReportsDecision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesLisa Osgood781-993-2606losgood@dresources.comDecision Resources, Inc.Christopher Comfort781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs
2. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
3. Boston Scientific Completes Acquisition of Asthmatx
4. Due to Rising Costs of Asthma and Chronic Obstructive Pulmonary Disease Drugs, Managed Care Organization Pharmacy Directors Will be Forced to Tighten Their Formularies
5. Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010
6. Boston Scientific to Acquire Asthmatx
7. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
8. FDAs New Safety Controls for LABA-Containing Drugs Will Impact Prescribing of Single-Agent ICS and LABA/ICS Combination Therapies for the Treatment of Asthma
9. Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA
10. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
11. Teva Respiratory to Host Phillies Asthma Awareness Night Featuring Free Asthma and Exercise-Induced Bronchospasm Screenings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... Feb. 23, 2017  The particle counters market ... 2021 from USD 275.9 million in 2016, at ... full report: http://www.reportlinker.com/p04718602-summary/view-report.html The ... pharmaceutical R&D, and growth in manufacturing industries in ... growth for particle counters. On the other hand, ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis and ... global Urinary Incontinence market. The research answers the following questions: ... for Urinary Incontinence and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... On February 22, ... a letter to withdraw previous guidance issued by the Obama Administration requiring ... issued in May 2016 by the Obama Administration came in response to a ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in Miami Beach to host its Swirl: Miami Wine Tasting Event on March ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... The American ... for ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. ... an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, ... raffle. Throughout the month of February, patients who visit Hamlin Dental Group will receive ... dinner for two at the Cheesecake Factory. , Tickets are available for routine ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
Breaking Medicine News(10 mins):